Immunological Monitoring in Remission Acute Myeloid Leukemia During Maintenance Therapy
In a study beginning in 1981 43 adult patients with acute myeloid leukemia (AML) in remission were treated with cytosine arabinoside (Ara-C) alternately combined with daunorubicin, thioguanine, or cyclophosphamide in maintenance therapy every 4 weeks. 22 of the 43 patients were randomized for chemotherapy (CT) only and 21 for chemo-immunotherapy (CIT). CIT patients received immunotherapy with additional neuraminidase-treated allogeneic viable blasts given between the chemotherapy courses. During maintenance therapy immunologic monitoring was carried out.
KeywordsAcute Myeloid Leukemia Maintenance Therapy Skin Test Acute Myelogenous Leukemia Cytosine Arabinoside
- 2.Bekesy JG, Holland JF, Flemminger F, Yates J, Henderson ES (1977) Immunotherapeutic efficacy of neuraminidase-treated allogeneic myeloblasts in patients with acute myelocytic leukemia. In: Chirigos MA (ed) Control of neoplasia by modulation of the immune system, pp 573–529Google Scholar